427 related articles for article (PubMed ID: 15536140)
1. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
Moser LR; Kalus JS
Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
[TBL] [Abstract][Full Text] [Related]
2. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
3. Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.
Kalus JS; Moser LR
Ann Pharmacother; 2005 Mar; 39(3):481-91. PubMed ID: 15701782
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
Wong GC; Giugliano RP
Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
[TBL] [Abstract][Full Text] [Related]
5. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
6. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
8. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Ferguson J
J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.
Borentain M; Montalescot G; Bouzamondo A; Choussat R; Hulot JS; Lechat P
Catheter Cardiovasc Interv; 2005 Jun; 65(2):212-21. PubMed ID: 15900551
[TBL] [Abstract][Full Text] [Related]
11. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
13. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
14. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Husted S; Kher A
Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
[TBL] [Abstract][Full Text] [Related]
15. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
Mukherjee D; Eagle KA
Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
[TBL] [Abstract][Full Text] [Related]
16. A randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart disease.
Chen JL; Chen J; Qiao SB; Guo YL; Wu YJ; Dai J; Yuan JQ; Qin XW; Yang YJ; Gao RL
Chin Med J (Engl); 2006 Mar; 119(5):355-9. PubMed ID: 16542576
[TBL] [Abstract][Full Text] [Related]
17. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
Marmur JD; Bullock-Palmer RP; Poludasu S; Cavusoglu E
J Invasive Cardiol; 2009 Dec; 21(12):653-64. PubMed ID: 19966370
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation.
Kereiakes DJ
Circulation; 2003 Oct; 108(16 Suppl 1):III22-7. PubMed ID: 14605016
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes.
Shimpi RA
J Invasive Cardiol; 2003 Aug; 15(8):460-5. PubMed ID: 12890880
[No Abstract] [Full Text] [Related]
20. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
